Superworth

Cadre price to free cash flow CDRE

Market value divided by free cash flow over the last twelve months, since 2022.

Today, Nov 2, 2026
17.3×
4-year median
24.6×
Against its 4-year history
7th
percentile: 0 is its lowest day, 100 its highest
4-year range
13.5× to 57.0×
Peer median
20.9×

Cadre's price to free cash flow is 17.3× as of Nov 2, 2026.

That is below its 4-year median of 24.6×, lower than on 93% of days in the last 4 years.

Over that time it ranged from 13.5× in Oct 2026 to 57.0× in Jan 2025.

The median for 10 medical instruments and supplies stocks of a similar size is 20.9×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far17.3×13.5×29.4×
202527.8×26.7×57.0×
202446.2×18.6×51.2×
202321.6×16.4×25.3×
202221.4×21.4×34.3×

Against its peers

Companies in Medical - Instruments & Supplies nearest Cadre's size, closest first, today.

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Cadre

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.